Categories: Reuters

U.S. to propose TV ads for drugs must include list prices

(Reuters) – The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, said on Monday it will propose requiring companies to include the price of their prescription medicines in television ads.

Health and Human Services (HHS) Secretary Alex Azar, in announcing the plan, dismissed suggestions by major U.S. drug companies that less stringent disclosures might be adequate.

Azar said HHS would soon propose the rule that would force companies to include the list prices paid by the government’s Medicare or Medicaid programs in direct-to-consumer commercials. The policy was previously suggested in President Donald Trump’s “blueprint” to lower U.S. drug prices.

“We will not wait for an industry with so many conflicting and perverse incentives to reform itself,” Azar said, speaking at the National Academy of Medicine’s Annual President’s Forum.

The proposed rule would work to inject greater transparency into the prices prescription drug manufacturers set and would give beneficiaries important information they need to make informed decisions based on cost, the U.S. Centers for Medicare & Medicaid Services said in a news release.

Earlier on Monday, the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry’s top U.S. lobbying group, announced that its members would include directions in their commercials for patients to find information about the potential price of medicines, such as company websites.

It did not pledge to include the list price in commercials, arguing that they do not reflect the final amount paid by patients as it excludes rebates and discounts drugmakers may offer. PhRMA said including the list price in commercials could discourage patients from seeking needed medical care.

PhRMA represents major U.S. companies, such as Abbvie Inc <ABBV.N>, Pfizer Inc <PFE.N> and Merck & Co <MRK.N>.

The industry will also launch a new platform that will give patients and providers cost and financial assistance information for branded medicines, the group said.

Under the proposed rule, the price to be posted in legible text at the end of an ad would be for a typical course of treatment for an acute medication, such as an antibiotic, or for a 30-day supply of medication for a chronic condition, like high blood pressure. HHS said it would maintain a public list of drug advertisements that do not comply.

(Reporting by Michael Erman in New York and Manogna Maddipatla in Bengaluru; Editing by Sai Sachin Ravikumar and Bill Berkrot)


Recent Posts

  • Reuters

Many migraine sufferers wary of alcohol as a headache trigger

By Carolyn Crist (Reuters Health) - - Many migraine sufferers avoid alcohol, saying it can trigger the severe headaches, a…

2 hours ago
  • Reuters

New breast cancer gene tests don’t faze women

By Lisa Rapaport (Reuters Health) - Women with breast cancer who get newer genetic tests to estimate their risk of…

2 hours ago
  • Reuters

New app may improve ability to focus

By Linda Carroll (Reuters Health) - For people who have trouble concentrating, help may be on the way through a…

3 hours ago
  • Reuters

Cancer survivors face stress from steep medical bills

By Lisa Rapaport (Reuters Health) - Cancer survivors have higher-than-average rates of medical financial hardship, a U.S. study suggests. Medical…

6 hours ago
  • Reuters

Study in WHO journal likens palm oil lobbying to tobacco and alcohol industries

(The original headline of this Jan. 8 story referred to a "WHO study". the study was published in the WHO's…

8 hours ago
  • Reuters

Chinese scientist who gene-edited babies fired by university

SHENZHEN, China (Reuters) - A Chinese scientist who created what he said were the world's first "gene-edited" babies evaded oversight…

11 hours ago